745041-30-9

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 745041-21-8 (2R,3S,4R)-1,3-O-benzylidene-1,2,3,4-nonanetetrol 
• 488-82-4 D-Arabitol 
• 100-52-7 benzaldehyde 
• 164576-09-4 4,5-anhydro-1,3-O-benzylidene-D-arabinitol 
• 164576-08-3 1,3-O-benzylidene-5-O-toluenesulfonyl-D-arabitol 
• 80924-06-7 1,3-O-benzylidene D-arabitol 
• 1333920-07-2 1,3-O-benzylidene-2-O-methanesulfonyl-1-xylo-1,2,3,4-nonanetetrol 
• 1333920-08-3 1,3-O-benzylidene-2-O-methanesulfonyl-4-O-p-nitrobenzoyl-D-arabino-1,2,3,4-nonanetetrol 
• 1333920-06-1 1,3-O-benzylidene-1-xylo-1,2,3,4-nonanetetrol 
• 110-53-2 1-Bromopentane 
• 99274-32-5 2,4-O-benzylidene-D-threose 

Downstream Products

• 1333920-11-8 2-azido-3,4-O-isopropylidene-1-((2,3,4-tri-O-benzyl-α-D-galactopyranosyl)thio)-D-ribo-3,4-nonanediol 
• 1333920-12-9 3,4-O-isopropylidene-2-tetracosanoylamino-1-((2,3,4-tri-O-benzyl-α-D-galactopyranosyl)thio)-D-ribo-3,4-nonanediol 
• 1333920-13-0 2-tetracosanoylamino-1-((2,3,4-tri-O-benzyl-α-D-galactopyranosyl)thio)-D-ribo-3,4-nonanediol 
• 1333920-15-2 2-hexacosanoylamino-3,4-O-isopropylidene-1-((2,3,4-tri-O-benzyl-α-D-galactopyranosyl)thio)-D-ribo-3,4-nonanediol 
• 1333920-16-3 2-hexacosanoylamino-1-((2,3,4-tri-O-benzyl-α-D-galactopyranosyl)thio)-D-ribo-3,4-nonanediol 
• 745041-39-8 2-azido-1,3-O-benzylidene-D-ribo-1,3,4-nonanetriol 
• 745042-02-8 (2S,3S,4R)-1-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyloxy)-2-(tetracosanoylamino)nonane-3,4-diol 
• 745041-79-6 (2S,3S,4R)-3,4-O-isopropylidene-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-2-tetracosanoylamino-1,3,4-nonanetriol 
• 745041-64-9 (2S,3S,4R)-2-azido-3,4-O-isopropylidene-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-1,3,4-nonanetriol 
• 745041-72-9 (2S,3S,4R)-2-amino-3,4-O-isopropylidene-1-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-1,3,4-nonanetriol 
• 383187-82-4 OCH 

Relevant academic research and scientific papers

Synthesis and biological evaluation of truncated α-galactosylceramide derivatives focusing on cytokine induction profile

A series of truncated analogs of α-galactosylceramide with altered ceramide moiety was prepared, and evaluated for Th2-biased response in the context of IL-4/IFN-γ ratio. Phytosphingosine-modified analogs including cyclic, aromatic and ethereal compounds

Synthesis of α-S-galactosylceramides with a truncated sphingoid chain

We present here a convenient synthesis of the truncated sphingoid iodide 15 from d-galactose, in which Mitsunobu reaction was utilized to retrieve successfully an unwanted intermediate, thereby increasing greatly the synthetic efficiency. Subsequent react

GLYCOLIPID DERIVATIVES, PROCESS FOR PRODUCTION OF THE SAME, INTERMEDIATES FOR SYNTHESIS THEREOF, AND PROCESS FOR PRODUCTION OF THE INTERMEDIATES

Novel glycolipid derivatives, where the substituent of the sphingosine base part is a short carbon chain alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted aryl group or substituted or unsubstituted aralkyl group and

Total synthesis of an immunosuppressive glycolipid, (2S,3S,4R)-1-O- (α-D-galactosyl)-2-tetracosanoylamino-1,3,4-nonanetriol

(Chemical Equation Presented) A practical and efficient total synthesis of (2S,3S,4R)-1-O-(α-D-galactosyl)-2-tetracosanoylamino-1,3,4-nonanetriol, OCH 1b, a potential therapeutic candidate for Th1-mediated autoimmune diseases, is described. The synthesis